3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
8
Lymphoma, Non-Hodgkin
5
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Burkitt Lymphoma
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Testicular Neoplasms
2
Prostatic Neoplasms
2
Penile Neoplasms
2
Ovarian Neoplasms
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Solid Tumors
1
Interventions
Oxaliplatin
5
S 1 (combination)
4
Irinotecan
4
pembrolizumab
3
IFL protocol
3
Fluorouracil
3
Bevacizumab
3
amminedichloro(2-methylpyridine)platinum(II)
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
MLN 8237
2
Leucovorin
2
Gemcitabine
2
Folfox protocol
2
Fecal Microbiota Transplantation
2
Drug Therapy
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
CGX1321
2
ulixertinib
1
tivozanib
1
titanium silicide
1
tislelizumab
1
sodium thiosulfate
1
sacituzumab govitecan
1
remune
1
plecanatide
1
phosphatidyltransferase, Clostridium butyricum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastrointestinal Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled